Conatumumab: a novel monoclonal antibody against death receptor 5 for the treatment of advanced malignancies in adults
Conatumumab: a novel monoclonal antibody against death receptor 5 for the treatment of advanced malignancies in adults
复制标题
DOI：
10.1517/14712598.2011.610788
复制
发表时间：
2011-11-01
影响因子：
4.6
通讯作者：
Heath, Elisabeth I.
中科院分区：
文献类型：
--
作者：
Bajaj, Madhuri;Heath, Elisabeth I.
对标准化疗难以治愈的晚期恶性肿瘤的治疗选择很少。Conatumumab是一种研究性的全人类单克隆激动剂抗体，针对人类死亡受体DR5，该受体在多种晚期癌症中表达。涵盖领域：将讨论基于体外、体内、I期和II期数据使用conatumumab的基本原理。专家意见：根据现有和已发表的数据，每2周20mg /kg剂量的Conatumumab在晚期肿瘤患者中显示出可接受的安全性和耐受性。进一步的临床试验正在评估conatumumab与化疗药物和靶向药物联合使用。
Introduction: Advanced malignancies that are refractory to standard chemotherapy have few treatment options. Conatumumab is an investigational, fully human monoclonal agonist antibody directed at human death receptor DR5, which is expressed in multiple advanced cancers.Areas covered: The rationale for the use of conatumumab based on in vitro, in vivo, Phase I, and Phase II data will be discussed.Expert opinion: Conatumumab, at a dose of 20 mg/kg every 2 weeks, has demonstrated acceptable safety and tolerability in patients with advanced tumors based on available and published data. Further clinical trials are underway evaluating the use of conatumumab in combination with chemotherapeutic and targeted agents.